BioArctic: Societal value of lecanemab in Japan published in

Stockholm, May 17, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of results from a simulation study evaluating the

Related Keywords

Uppsala , Uppsala Lan , Sweden , Japan , Stockholm , China , Swedish , Japanese , Oskar Bosson , Gewinn Nur , Alzheimer Clinical Trial Consortium , Alzheimer Network Trials Unit , National Institute On , Washington University School Of Medicine , National Medical Products Administration , Devices Agency , Uppsala University , Vp Communications , Advisory Committee , European Medicines Agency , Drug Administration , Ministry Of Health , National Institutes Of Health , Nasdaq Stockholm , Brand Name , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Medical Devices Agency , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Commercialization Agreement , Nasdaq Stockholm Large Cap , Bioarctic , Societal , Value , Lecanemab , Published , Eurology , Therapy ,